7,398.33

+44.60

+0.61%

51,428.75

-94.31

-0.18%

24,644.17

+329.17

+1.35%

2,756.31

+26.42

+0.97%

4.8570

+0.0200

+0.41%

24.67

-3.51

-12.45%

4,077.20

-36.30

-0.88%

75,601.34

-619.19

-0.81%

Crude Oil Dec 26

90.99

+0.47

+0.52%

US Private Equity

10,760.93

-143.81

-1.32%

NasdaqCM - Nasdaq Real Time Price USD

Revelation Biosciences, Inc. (REVBW)

0.0032 -0.0018 (-36.00%)

As of 9:41:02 AM EST. Market Open.

Loading Chart for REVBW

Chart Range Bar

Interval:

In partnership with ChartIQ

Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026

Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026

Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026

Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

REVB Approaching a Critical Inflection Point

REVB Approaching a Critical Inflection Point

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury

Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revelation Biosciences Announces Adoption of Stockholder Rights Plan

Revelation Biosciences Announces Adoption of Stockholder Rights Plan

Revelation Biosciences Expands Acute Kidney Injury Advisory Board

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

REVB Poised for Big Year

REVB Poised for Big Year

Mobilize your Website

View Site in Mobile | Classic

Share by: